Current Report Filing (8-k)
April 20 2022 - 07:38AM
Edgar (US Regulatory)
0000001800
false
Common Shares, Without Par Value
ABT
0000001800
2022-04-20
2022-04-20
0000001800
us-gaap:CommonStockMember
exch:XCHI
2022-04-20
2022-04-20
0000001800
us-gaap:CommonStockMember
exch:XNYS
2022-04-20
2022-04-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Common Shares, Without Par Value |
|
ABT |
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
April 20, 2022
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
Illinois |
|
1-2189 |
|
36-0698440 |
(State or other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of Incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
Title of Each Class |
Trading
Symbol(s) |
Name of Each Exchange
on Which Registered |
Common
Shares, Without Par Value |
ABT |
New
York Stock Exchange
Chicago
Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition |
On April 20, 2022, Abbott Laboratories announced its results of operations
for the first quarter 2022.
Furnished as
Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release,
Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial
measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring
actions, cost reduction initiatives, a voluntary recall, certain regulatory costs, certain litigation, the impairment of certain assets,
tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior
years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization
expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally
assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information
to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing
business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses.
Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial
measures prepared in accordance with GAAP.
| Item 9.01 | Financial Statements and Exhibits |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
|
|
Date: April 20, 2022 |
By: |
/s/ Robert E. Funck, Jr. |
|
|
Robert E. Funck, Jr. |
|
|
Executive Vice President, Finance and Chief Financial Officer |
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2023 to Mar 2024